




**CME FOUNDATION OF INDIA**



**NOVEL THERAPY TO  
TREAT CKD ANEMIA IN INDIA**

**EVENT REPORT**

## About Workshop

The **CME Foundation of India** organized an academic workshop on **Novel Therapy to Treat CKD Anemia in India** on 14<sup>th</sup> February 2026 at ESIC hospital, Somwaripeth, Nagpur. The session aimed to address the unmet clinical needs in the management of anemia associated with chronic kidney disease (CKD) and to explore emerging therapeutic approaches in this domain.

The workshop was attended by physicians and nephrologists from ESIC Hospital and surrounding centers. The session by **Dr. Ashish Bhojar** covered multiple aspects of CKD anemia management, such as understanding the growing challenge in CKD anemia, limitations of current therapies, desidustat as a novel therapy in CKD management, its mechanism, and practical integration in clinical practice.

**Date:** 14<sup>th</sup> February 2026

**Venue:** ESIC Hospital, Somwaripeth, Nagpur

**No. of participants:** 34

## Agenda

**Date:** 14<sup>th</sup> February 2026

**Time:** 1:00 p.m. to 2:00 p.m.

Topics	Speaker	Timings
Registration		1:00 p.m. – 1:10 p.m.
Welcome Note		1:10 p.m. – 1:15 p.m.
Novel Therapy to Treat CKD Anemia in India	Dr. Ashish Bhojar M.B.B.S., D.N.B. (Medicine), D.N.B. (Nephrology)	1:15 p.m. – 1:55 p.m.
Vote of Thanks Followed by Lunch		1:55 p.m. – 2:00 p.m.

## Summary of the Novel Therapy to Treat CKD Anemia in India

### The Increasing Burden of Anemia in CKD

Dr. Ashish Bhoyar opened the session by highlighting the high prevalence of anemia among patients with chronic kidney disease (CKD) in India. He underscored its far-reaching consequences on clinical outcomes, patient quality of life, and overall healthcare costs. CKD-associated anemia, he explained, arises from a complex interaction of factors including iron deficiency, persistent inflammation, and reduced erythropoietin synthesis. The convergence of these mechanisms makes effective management challenging and underscores the need for newer therapeutic strategies beyond standard treatments.

### Limitations of Existing Treatment Options

The discussion then addressed current management approaches, such as erythropoiesis-stimulating agents (ESAs) and iron therapy. Dr. Ashish Bhoyar pointed out several shortcomings of these modalities, including inconsistent efficacy, safety concerns, and limited accessibility within the Indian healthcare system. These constraints frequently result in suboptimal hemoglobin control, repeated dose adjustments, and poor treatment adherence, leaving significant unmet needs in CKD-related anemia care.

### Desidustat: An Emerging Treatment Strategy

A major focus of the workshop was Desidustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. Dr. Ashish Bhoyar explained that Desidustat works by enhancing endogenous erythropoietin production, improving iron metabolism, and lowering hepcidin levels. By addressing multiple pathogenic pathways simultaneously, it represents a promising alternative to injectable ESAs, with the potential to improve convenience, safety, and patient compliance.

## **Clinical Evidence for Desidustat**


Dr. Ashish Bhojar reviewed pivotal clinical trial findings demonstrating Desidustat's efficacy in raising and sustaining hemoglobin levels across diverse CKD populations. Its favorable safety and tolerability profile was also emphasized. In addition, real-world clinical data were shared, reinforcing its effectiveness in both dialysis-dependent and non-dialysis CKD patients.

## **Incorporating Desidustat into Routine Practice**

The session concluded with practical guidance on patient selection, dosing strategies, monitoring protocols, and key considerations for integrating Desidustat into everyday clinical practice. Participants exchanged actionable insights aimed at optimizing therapy, improving adherence, and achieving better patient outcomes—reinforcing a patient-focused approach to modern CKD anemia management.

**At the end of the Conclave, the CME Foundation of India extended its sincere gratitude to the speaker and delegates for attending the conclave and acknowledged Zydus Lifesciences Ltd., the industry partner, for their valuable support and contribution to the success of the Conclave.**









Developed by:

## **CME FOUNDATION OF INDIA**

Building "A" Sahney Business Centre, 27 Kiroli Road, Vidyavihar (W), Mumbai - 400086  
Tel: +91 22 61798600 | Website: [www.cmefi.co.in](http://www.cmefi.co.in)